U
NBIX icon

UBS’s Neurocrine Biosciences NBIX Stock Holding History

UBS’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$506K Buy
32,300
+31,100
+2,592% +$465K ﹤0.01% 4267
2014
Q2 		$18K Sell
1,200
-9,200
-88% -$130K ﹤0.01% 8213
2014
Q1 		$167K Buy
10,400
+10,100
+3,367% +$173K ﹤0.01% 5400
2013
Q4 		$3K Sell
300
-9,600
-97% -$93.7K ﹤0.01% 9866
2013
Q3 		$112K Buy
9,900
+3,100
+46% +$42.6K ﹤0.01% 5887
2013
Q2 		$91K Buy
+6,800
New +$83.5K ﹤0.01% 6027

Other funds holding NBIX

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's NBIX Position: Q3 2014 in Review

UBS reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q3 2014, selling an estimated $57K and leaving 25,159 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #4505.

UBS first reported a position in NBIX in Q2 2013 and has held it in 6 quarters since. The position peaked at $534K in Q1 2014. 133 funds tracked by Wall St. Rank hold NBIX as of Q3 2014.

  • UBS held 25,159 shares of Neurocrine Biosciences worth $394K as of Q3 2014.
  • UBS sold 3,815 Neurocrine Biosciences shares in Q3 2014, an estimated $57K.
  • Neurocrine Biosciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4505 holding.
  • UBS first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 6 quarters since.
  • UBS's Neurocrine Biosciences position peaked at $534K in Q1 2014.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.